NCT00317252 is a Phase 2 clinical trial of Hold ACEI or ARB in Kidney Failure, sponsored by Hamilton Health Sciences Corporation.

Who is sponsoring NCT00317252?

NCT00317252 is sponsored by Hamilton Health Sciences Corporation.

What drugs are being tested in NCT00317252?

Interventions in NCT00317252: Hold ACEI or ARB.

What condition does NCT00317252 study?

NCT00317252 studies Kidney Failure.

Is NCT00317252 still recruiting?

NCT00317252 is currently completed. Last updated 19 October 2012.

Last reviewed 2012-10-19 · How we verify

NCT00317252

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Angiotensin Converting Enzyme Inhibitors and Contrast Induced Nephropathy in Patients Receiving a Cardiac Catheterization "The CAPTAIN Trial"

Completed Phase 2 Last updated 19 October 2012

What this trial tests

Phase 2 trial testing Hold ACEI or ARB in Kidney Failure in 220 participants. Completed in 1 March 2012.

Timeline

1 July 2006

Primary endpoint
1 March 2012

1 March 2012

Quick facts

Lead sponsor	Hamilton Health Sciences Corporation
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	220
Start date	1 July 2006
Primary completion	1 March 2012
Estimated completion	1 March 2012
Sites	1 location across Canada

Drugs / interventions tested

Hold ACEI or ARB — full drug profile →

Conditions studied

Kidney Failure — all drugs for Kidney Failure →

Sponsor

Hamilton Health Sciences Corporation — full company profile →

Who can join

Eligibility, any sex, with Kidney Failure. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Contrast induced nephropathy (creatinine rise of 44umol/L or 25% compared to the pre-randomization creatinine level) at 48-96hrs
Time frame: 48 - 96 hours post-cardiac catheterization

Sponsor's own description

The purpose of this study is to determine if patients should stop taking their angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) around the time of their angiogram in order to prevent contrast induced nephropathy (CIN).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

ACE-I/ARB therapy prior to contrast exposure: what should the clinician do?
Kalyesubula R, Bagasha P, Perazella MA. · · 2014 · cited 14× · PMID 24605330 · DOI 10.1155/2014/423848

Verify or expand the search:

Other recruiting trials for Kidney Failure

Currently open trials in the same condition.

NCT07492511 — Renal and Hepatic Abnormal Doppler Patterns in Trauma · recruiting
NCT06243731 — A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation · recruiting
NCT06642597 — STarting incrEmental Prescription of Peritoneal Dialysis · NA · recruiting
NCT06343727 — A High Protein Egg White Pudding for People With Kidney Failure (HiPE KF) · NA · recruiting
NCT07053462 — CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk · Phase 1, PHASE2 · recruiting

Other Hamilton Health Sciences Corporation trials

Trials by the same sponsor.

NCT06567808 — Prevention of Infections in Cardiac Surgery (PICS): a Cluster-randomized Factorial Cross-over Trial · Phase 4 · not yet recruiting
NCT07118696 — Evaluating a Shorter, Rifampicin-Based Treatment for People With Less Severe Tuberculosis Disease · Phase 3 · not yet recruiting
NCT07027436 — Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Su · Phase 3 · not yet recruiting
NCT06908694 — Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy · Phase 4 · recruiting
NCT06836024 — A Trial of Actazin Versus PEG 3350 for Maintenance Therapy in Children With Constipation · Phase 2, PHASE3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00317252 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hamilton Health Sciences Corporation
Last refreshed: 19 October 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00317252.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing